Skip to main content

Table 4 Subgroup analyses for the outcome of event-free survival

From: Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis

Subgroups

No. of studies

HR (95% CI)

I2 (P value)

Population

 Children

6

5.62 (3.75–8.42)

3.2% (0.40)

 Mixed adult and children

2

3.60 (1.72–7.51)

65.2% (0.09)

Design

 Prospective

5

5.33 (2.88–9.86)

57.6% (0.05)

 Retrospective

3

4.59 (2.89–7.27)

0 (0.73)

Detection method

 PCR

6

4.97 (2.93–8.44)

49.2% (0.08)

 FC

2

4.77 (3.31–6.87)

0 (0.70)

Adjustment

 Adjusted

4

4.56 (2.64–7.88)

48.9% (0.12)

 Crude

4

5.18 (2.94–9.11)

24.4% (0.27)